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Abstract: Acute myeloid leukemia (AML) is an aggressive malignancy, which is highly heterogeneous
with regard to chemosensitivity and biological features. The AML cell population is organized in a
hierarchy that is reflected in the in vitro growth characteristics, with only a minority of cells being able
to proliferate for more than two weeks. In this study, we investigated the ability of AML stem cells to
survive and proliferate in suspension cultures in the presence of exogenous mediators but without
supporting non-leukemic cells. We saw that a high number of maintained stem cells (i.e., a large
number of clonogenic cells after five weeks of culture) was associated with decreased overall survival
for patients receiving intensive chemotherapy; this prognostic impact was also detected in the
multivariate/adjusted analysis. Furthermore, the patients with many clonogenic cells presented more
frequently with mutations in transcription-related genes, and also showed a higher abundance of
proteins involved in transcription at the time of diagnosis. In conclusion, the growth characteristics
of the long-term proliferating leukemic stem cells seem to have an independent prognostic impact in
human AML, and these characteristics appear to be reflected by the mutational landscape and the
proteome of the patients at the time of diagnosis.
Keywords: acute myeloid leukemia; clonogenic cells; colony formation; cytokines;
differentiation; transcription
1. Introduction
Acute myeloid leukemia (AML) is an aggressive malignancy, which mainly affects the elderly.
It is characterized by an accumulation of immature myeloblasts in the bone marrow [1]. The backbone
of treatment is intensive chemotherapy, potentially combined with stem cell transplantation. Still,
overall survival is low due to a high relapse rate, and the high number of elderly or unfit patients,
who cannot undergo the intensive and potentially curative treatment [2].
Acute myeloid leukemia is a highly heterogeneous malignancy and prognosis, and thus overall
survival is correlated with both cytogenetics and specific gene mutations, such as FMS-related tyrosine
kinase 3 internal tandem repeats (Flt3-ITD; unfavorable) and nucleophosmin (NPM1; favorable in
absence of a coinciding Flt3-ITD) mutations [3]. Morphologically, AML is classified into eight distinct
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categories according to the French-American-British system (FAB M0-7), which defines at which
stage in hematopoiesis maturation arrest occurs [4,5]. Cell differentiation is further reflected by
downregulation of the CD34 stem cell marker upon maturation [6].
AML cell populations have a hierarchical organization, and a major part of the cells will undergo
spontaneous (i.e., stress-induced) apoptosis during the first 3–5 days of in vitro culture [7,8]. However,
for some patients, a subset of cells will still proliferate after 2–8 weeks despite the initial apoptosis [9],
and our present long-term cultures correspond to these previous in vitro assays for AML stem
cells [7]. Furthermore, AML stem cells can also be assayed by xenografts, which is achievable mainly
for cells from patients with high-risk leukemia [10]. Finally, total AML cell populations seem to
reflect at least certain characteristics of the leukemic stem cells that are thought to be responsible for
chemoresistance and leukemia relapse because gene expression and epigenetic profiles of the overall
population are associated with prognosis [11,12]. Based on these observations, our hypothesis is that
the ability of long-term in vitro growth in the absence of AML-supporting non-leukemic cells differs
between patients. This capacity of long-term proliferation reflects a clinically relevant difference in
the cellular ability to survive and proliferate under suboptimal conditions and is probably caused by
differences in regulation of proliferation and/or balance between pro- and anti-apoptotic signaling.
To identify these mechanisms, we characterized a large group of patients with regard to long-term
proliferation. Furthermore, to identify possible molecular mechanisms contributing to stress-resistance
(i.e., long-term in vitro survival and proliferation) we also performed transcriptomic and proteomic
comparisons of primary AML cells with or without long-term in vitro proliferation.
2. Results
2.1. Long-Term In Vitro Proliferation of AML Cells in the Absence of Supportive Non-Leukemic Cells Is
Detected Only for a Subset of Patients
Primary AML cells derived from 68 unselected patients (Table 1) were cultured in suspension
(six-well culture plates); the culture medium was only supplemented with thrombopoietin (TPO), Flt3
ligand (Flt3L), stem cell factor (SCF), granulocyte-macrophage colony-stimulating factor (GM-CSF),
and interleukin 3 (IL-3). After 35 days, the non-adherent cells were harvested and thereafter seeded
in methylcellulose medium (MethoCultTM H4434 containing erythropoietin, EPO) and incubated for
an additional 14 days before the number of colonies was estimated. Thus, the cells were cultured for
a total of 7 weeks, and clonogenic cells could then be detected for 38 of the 68 patients. A minority
of colonies of erythroid origin (i.e., presenting with morphological signs of hemoglobinization) were
detected for 16 of the 38 patients, whereas two exceptional patients showed only erythroid colonies.
Thus, non-erythroid colonies dominated for the large majority of patients. The number of colonies
obtained from the parallels of samples containing 25,000 and/or 50,000 seeded viable cells per well
were back calculated to the initial 2 × 106 cells, taking into consideration that cells from 20 cultures
had been removed during the course of suspension culture in order to prevent overgrowth with cell
density exceeding 2 × 106 cells/mL. The number of adjusted colonies showed a considerable variation
among patients and ranged from 1.5 up to 35,050 colonies per 2 × 106 initial cells (median number:
324 colonies).
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Cell Morphology Cell Genetics
Age De novo AML 45 Cytogenetics
Median (yrs) 64 Favorable 7
Range (yrs) 18–92 Secondary AML Intermediate 5
MDS 10 Normal 35
Gender CMML 2 Adverse 15
Females 33 CML 1 n.d. 6
Males 35 CLL 1
MF 3 Flt3 mutations
FAB
classification PV 1 ITD
2 16
M0 4 Chemotherapy 2 Wild-type 2 39
M1 17 n.d. 13
M2 13 AML relapse 1 7
M4 15 NPM1 mutations
M5 14 CD34 receptor Mutated 20
n.d. 5 Negative (≤20%) 21 Wild-type 33
Positive (>20%) 41 n.d. 15
n.d. 6
Flt3 plus NPM1 mutation 9
1 Three of the patients had a relapse of secondary AML. 2 One patient in each group has a point mutation at D835.
n.d.: not determined. Abbreviations: MDS: myelodysplastic syndrome; CMML: chronic myelomonocytic leukemia;
CML: chronic myeloid leukemia; CLL: chronic lymphocytic leukemia; MF: myelofibrosis; PV: polycytemia vera;
ITD: internal tandem repeat.
We estimated the number of viable cells after the initial five weeks of suspension cultures, and this
number showed a significant correlation with the capacity of colony formation (Kendall’s tau-b:
r = 0.431; p < 0.0001). We further observed borderline correlation with peripheral blood blast count
(Kruskal-Wallis test, p = 0.055; data from relapse patients were censored) as the median count increased
from 40.8 × 109 blasts/L for cultures with less than 0.5 × 106 viable cells to 105 × 109 blasts/L
for cultures containing more than 2.0 × 106 viable cells. We defined a threshold of 200 colonies,
corresponding to 0.01% long-term proliferating cells, to divide the patients into groups with few
and many colonies, respectively. We did this in order not to overestimate the significance of a few
observed colonies, which in case of a high cell number can lead to a rather high adjusted colony number.
The group with few colonies then comprised 16 patients with a median of 19 colonies whereas the
group with many colonies contained 22 patients with a median of 1367 colonies per 2.0 × 106 seeded
cells. The number of viable cells after five weeks in suspension culture varied considerably between
the groups with no or few detectable colonies on one side and the group of cultures with >200 colonies
on the other side (Table 2). Thus, it appears as if cultures with few colonies have more in common with
the cultures without detectable colonies, as compared to the group with more than 0.01% long-term
proliferating cells. Using this definition, only 1/30 cultures with less than 0.5 × 106 viable cells showed
colony formation as opposed to only 2/14 cultures with more than 2.0 × 106 viable cells that did not
form at least 200 colonies (Fisher’s exact test: p < 0.0001).
Table 2. Overview of median and range values for colony number and cell population for the groups
without detectable colonies, with few colonies and with many colonies.
Number of Colonies
Not Observed 1–200 >200
Colony number 0 19 (1.5–180) 1367 (285–35,050)
Viable cell number (106) 0.26 (0–3.06) 0.18 (0.01–2.25) 2.46 (0.30–53.5)
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2.2. The Capacity of Cytokine-Supported Long-Term In Vitro Proliferation Is Not Associated with Patient Age,
Morphological Differentiation, CD34 Expression, Karyotype, or Molecular Genetic Abnormalities
In agreement with previous results [13], the capacity of long-term AML cell proliferation in the
absence of supportive cells was not associated with the differentiation status of the primary AML
cells at the time of diagnosis, i.e., cultures with and without this capacity did not differ with regard
to morphological signs of differentiation (FAB classification) or expression of the CD34 stem cell
marker. Furthermore, apart from cell number colony formation after long-term culture appeared
to be independent of common prognostic factors such as patient age, hemoglobin levels, peripheral
blood blast count, cytogenetics, NPM1 mutations, and secondary or relapsed versus de novo AML
(an overview of patient details is provided in Supplementary Table S1). Only Flt3-ITD positive cells
showed a non-significant trend towards a higher percentage of clonogenic cells because 20% of cultures
with <200 colonies presented with Flt3-ITD, as opposed to 45% of cultures with higher colony numbers.
Thus, at least in this patient cohort, the capacity of long-term in vitro proliferation in the absence of
non-leukemic supportive cells seems to be essentially independent of the genetic abnormalities with
an established prognostic impact.
2.3. A high Frequency of AML Cells Showing Long-Term Cytokine-Supported Proliferation Is Associated with
Reduced Survival for Patients Receiving Intensive Anti-Leukemic Therapy
We compared the overall survival for patients whose blasts did or did not show long-term
cytokine-supported proliferation; this comparison included only relatively young and fit consecutive
patients with newly diagnosed AML who had completed their intensive and thus potentially curative
induction therapy followed by the planned consolidation treatment. The 18 patients showing long-term
proliferation were compared with the 17 patients where long-term proliferation supported by cytokines
alone was not detectable. Overall survival did not differ between these two groups of patients and
the 2-years survival was 40%. However, when we analyzed the quantitative instead of the qualitative
differences in long-term proliferation (i.e., the number of colonies/clonogenic cells after 5 weeks of
suspension cultures), we detected that the subset of patients with a high number of clonogenic cells
(>200 colonies) showed decreased overall survival (median overall survival for patients with no/few
detectable colonies being 2.4 years as compared to 8 months for patients with many colonies; log-rank
test: 0.006; Figure 1).
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We also performed a multivariate analysis including the known prognostic parameters age
(younger or older than 60 years), Flt3-ITD, NPM1 insertions, favorable and adverse/intermediate
cytogenetics and disease etiology (secondary versus de novo AML) in addition to the number of
colonies (below or above 200 colonies) (Table 3). In the Cox regression analysis, two parameters
emerged as independent risk factors for reduced survival: Patient age (hazard ratio, HR = 5.67;
p = 0.011) and colony number (HR = 5.82; p = 0.005). Because the mutation status and/or cytogenetics
for four patients were missing (three patients without detected colonies, one with >200 colonies;
no long-term survivors), the latter analysis only contained 31 out of the 35 patients with survival
data. The lack in associations between prognosis and Flt3/NPM1 mutations is most likely due to the
relatively small number of heterogeneous patients in our cohort and a rather large overlap of patients
in the groups with NPM1-insertions and Flt3-ITDs, as 7/18 patients with acquired mutations present
with alterations in both genes.
Table 3. Multivariate (adjusted) hazard ratio analysis for parameters associated with prognosis in AML.
Significant p-values are highlighted.
Variable Adj. HR 95% CI p-Value
Age (≥60 years) 1 5.67 1.49–21.56 0.011
Colony number (≥200) 5.82 1.72–19.66 0.005
Flt3-ITD 1.83 0.48–6.92 0.377
NPM1-insertion 2.33 0.65–8.39 0.194
Etiology (de novo) 0.44 0.05–3.89 0.458
Favorable cytogenetics 0.78 0.11–5.61 0.802
Unfavorable/intermediate cytogenetics 0.58 0.11–3.00 0.513
1 Reference value, i.e., age ≥ 60 years is a risk factor. HR: hazard ratio; CI: confidence interval.
2.4. Increased Levels of HGF and IL-1RA during Long-Term Suspension Culture Are Associated with
Maintenance of Clonogenic Cells during Culture
We investigated long-term AML cell proliferation in the presence of exogenous cytokines.
However, primary AML cells themselves show constitutive release of a wide range of soluble
mediators [14,15]. To characterize the mediator release by the leukemic cells during long-term
suspension culture we measured the supernatant levels of 19 constitutively released mediators after
7 and 35 days of culture. We first investigated whether the levels of these mediators varied during
the five weeks of suspension cultures (Wilcoxon signed-rank test for paired samples; week 5 vs. week
1 values), and whether these variations showed any associations with proliferation/viability during
short-term culture, specific AML subgroups (i.e., FAB classification, cytogenetics, gene mutations,
disease etiology) or colony formation. First, five of the 19 mediators showed no significant
variation (due to a large number of comparisons, the significance level was set to 0.01) during
the culture period: the chemokines (CCL5 and CXCL5), the interleukins (IL-1β and IL-6), and
granulocyte colony-stimulating factor (G-CSF). Second, the levels of the eight mediators CCL2-4,
CXCL8, IL-1 receptor antagonist (IL-1RA), matrix metalloproteases (MMP) 1 and 2, and cystatin C
significantly increased during the suspension culture for all patients, except for those without detectable
cytokine-dependent proliferation in the one-week 3H-thymidine assay and/or extensive spontaneous
in vitro apoptosis characterized by less than 30% viable cells after two days of suspension culture.
A gradual increase during long-term suspension culture of these eight cytokines thus seems to reflect
that viable cells are still present during culture. Third, an increase during culture for the five mediators
CXCL1/10, MMP-9, serpin E1 and tumor necrosis factor α (TNFα) was especially seen for patient cells
without monocytic differentiation (i.e., FAB M0-2; Supplementary Figure S1). Finally, an increase in
hepatocyte growth factor (HGF) was associated with cultures containing >0.5 × 106 viable cells after
five weeks of suspension culture, and with colony forming cultures (Figure 2).
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Figure 2. Differences in hepatocyte growth factor (HGF) secretio e e ent on cell population and
colony number. (A) HGF concentrations do not significantly increase bet een eek 1 and week 5 for
cultures containing less than 0.5 × 106 viable cells after 5 weeks of culturing. (B) Increase in HGF levels
is more pronounced in cultures with detectable colonies (right). Note the large overlap between the
patients with higher cell numbers and colony formation.
On the other hand, when we compared the cytokine secretion ratios between different patient
subgroups (Mann-Whitney U-test; week 5/week 1 ratios; p ≤ 0.01), different patterns were observed
for seven mediators: CCL2, CCL3, HGF, IL-1RA, MMP-9, cystatin C, and TNFα. Higher ratios of
CCL2, CCL3, and cystatin C were observed for cells without NPM1 insertions and for CD34+ cells
(Supplementary Figure S2). Furthermore, higher secretion ratios of IL-1RA, MMP-9 and TNFα were
associated with FAB M0-2 (Supplementary Figure S3). On the other hand, the MMP-9 decrease over
time was linked with cells showing morphological changes (i.e., plastic adherence, increased cellular
size and/or presence of pseudopodia) over time (p < 0.001). Finally, higher ratios of HGF (p = 0.004)
and borderline of IL-1RA (p = 0.014) were observed for cultures with colony forming cells (Figure 3;
Sup lementary Tables S2 and S3). How ver, th increase in HGF was most pron unced f r the patient
group w th few col ies. The release ratios for the latter cytokines showed also a weakly positive
correlation with the number of colonies: IL-1RA (Kendall’s tau-b: r = 0.203; p = 0.029) and HGF
(r = 0.251; p = 0.007).
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2.5. High Constitutive Cytokine Release Is Associated with an Altered AML Cell Phenotype during the Initial
Five Weeks of Suspension Culture
We reproduced the results from a previous study of primary AML cells [14], which showed
that high constitutive release of a wide range of soluble mediators during short-term in vitro culture
is associated with signs of monocytic differentiation (FAB M4/5; Supplementary Table S4) and the
favorable inv(16) abnormality with especially high secretion levels at week 1 and 5, respectively.
Also in concurrence with the former study, NPM1-insertions and/or absence of the stem cell marker
CD34 were associated with lower mediator levels. However, according to the current study, the AML
cell population showing morphological alterations after 2–3 weeks of suspension culture had the
highest absolute mediator levels of all samples (Mann-Whitney U-test; p ≤ 0.01): initial (week 1)
high levels for CCL4, CXCL8, IL-1RA, HGF, MMP-1/9, and cystatin C; and persistent (week 1
and week 5) high levels for CCL2, CXCL5/10, IL-1β, G-CSF, and TNFα (Supplementary Table S4).
The presence of morphological changes was associated with monocytic differentiation of the primary
cells (FAB M4/5; Fisher’s exact test; p = 0.011). All cells with the inv(16)/t(16;16) abnormalities also
showed a change in their phenotype, high cytokine levels and in general absence of colony formation,
with exception of the single t(16;16) patient (396 colonies). Interestingly, there was, in general, no distinct
correlation between constitutive cytokine secretion levels and the number of viable cells after five
weeks in suspension culture or colony number after seven weeks of culture (Supplementary Table S5).
Long-term maintenance seems rather to be associated with a higher relative increase in HGF and
probably also in IL-1RA during culture (Section 2.4).
We further performed an unsupervised clustering (Figure 4) including the 14 mediators,
which were secreted at significantly higher levels in those cell cultures that showed morphological
alterations during long-term culture. In the cluster, the patients divided into two groups: Low and high
initial cytokine release. As expected from previous results [14], all five patients with inv(16)/t(16;16)
and a majority of 72% of FAB M4/5 patients (Fisher’s exact test; p = 0.005) clustered in the high
release group. Furthermore, 73% of cultures showing morphological signs of differentiation (increased
cellular size and/or presence of pseudopodia) after 5 weeks in suspension clustered in the high release
group (Fisher’s exact test; p = 0.001). Regarding colony formation, there was no significant difference
between the two groups. Intriguingly, morphological alterations during suspension culture appeared
to correlate with increased patient survival, independent of colony number (log-rank test p = 0.006;
Supplementary Figure S4).
2.6. Gene Expression and Mutation Profiling Identifies Differences between Patient Groups with High and Low
Numbers of Clonogenic Cells
Using JExpress, we performed a feature subset selection (FSS)/Anova microarray analysis
comparing 10 unselected patients with many (>200 colonies) colony forming units (CFUs) with
17 patients with fewer colonies. We set the cut-off to an absolute t-score of 4.00, corresponding
to p < 5.0 × 10−4. We found 14 genes (including two probes for C3orf38) differentially expressed,
thereof 12 mapped genes. Five of these genes were overexpressed in cultures with <200 colonies
(Figure 5; Table 4; Supplementary Table S6). Most of the genes are associated with metabolism and
energy pathways (NUDT19, P2RX4, and TMLHE), whereas C3orf38 is possibly linked with apoptosis.
The seven upregulated genes for cultures with many colonies, on the other hand, include genes that
are linked with mitosis (KIAA1383 and PARD6A), invasion and metastasis (LMLN and PARD6A),
and protein folding (HSPA12A). The most interesting gene, however, might be the proto-oncogene
GRB10 (coding for growth factor receptor-bound protein 10) which has been investigated in AML,
where it was linked to leukemogenesis [16] and relapse due to resistant disease [17].
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M4/5) are overrepresented in the high release group. On the other hand, colony number correlates
with cell number but not with cytokine expression.
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colony forming cells. Probes of differentially expressed mRNA with an absolute t-score > 4.00 were
median norm lized and log transformed p ior to clustering. C3orf38 represents the mean value for the
two gene probes. Red and blue color represent u - and downregulated enes, resp ctively. RPS4Y1,
a gene encoded o the Y-chromosome, was excluded from the cluster as it divide the patients by gender
rather than colony number; the patient subgroups presented by the microarray coincidentally contained
70% female patients in the high colony subgroup, and 82% male patients in the low colony subgroup.
Table 4. Classification of the genes that were found to be differentially expressed for patient populations
with >0.01% c onogen c cells. The upregulated genes are associat d with c ll cycl and signaling,
whereas the do nregulated genes most y are linked with m tabolism. For details on the enco ed
protei s, see Supplementary Table S6.
Classification Based on Protein Function
Gene Expression in AML Population with Colony Formation
Upregulated Downregulated




Signaling, transport APOL1; GRB10; PPADDC3/PLPP7 P2XR4; TMLHE
Metabolism NUDT19; TMLHE
Unknown LOC642082; LOC648605
Furthermore, for 35 patients—thereof eight with >200 colonies—we have more in-depth
information about the mutational landscape including 35 additional mutations to Flt3-ITD and
NPM1-insertions, which all are associated with AML (Supplementary Table S7). It appears as if
mutations in genes, where the products are involved in chromatid separation (i.e., the chromatid
modifier ASXL1 and subunits of the cohesin complex, namely RAD21, SMC1A and STAG2), are more
frequent among patients with >0.01% clonogenic cells (0.75 as compared to 0.15 mutations/p tient;
Fisher’s exact test p = 0.010).
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2.7. Gene Expression Profiling Identifies Differentially Expressed Genes for Both Cultures Which Present with
an Altered AML Phenotype and Cultures with Erythroid Colonies
We performed FSS analysis as described in Section 2.6 for cultures that differed in their AML blast
phenotype, and for cultures with and without colonies of erythroid origin.
First, FSS identified 61 probes coding for 35 annotated genes which were differentially expressed
between the patient groups with (10 patients) and without (17 patients) stable AML cell phenotype
during long-term suspension culture (Section 2.5; Supplementary Figure S5; Supplementary Table S8).
The encoded proteins fulfil a wide range of functions with signaling (7 genes), transcription (8 genes)
and metabolism (10 genes) being the most prominent (Supplementary Table S9). Five of these genes
have been studied in AML (see [16,18–22]).
Second, FSS identified 36 differentially expressed probes, thereof 23 annotated genes (Section 2.1;
Supplementary Figure S6; Supplementary Table S10), which differentiated the cultures with erythroid
colonies (7 patients) from those containing only myeloid colonies (9 patients). Most of the genes were
upregulated in the subset with erythroid colonies and coded for proteins involved in metabolism
(5 proteins) and transcription (4 proteins; Supplementary Table S11). Two of the upregulated genes
have been investigated in AML (see [23–25]).
2.8. Proteomics Analysis Identifies Proteins Involved in Transcription to Be More Abundant for Patients with a
High Number of Clonogenic Cells
We performed both proteomic and phosphoproteomic analyses on cells from 15 consecutive
AML patients (8 with no/few and 7 with many colonies) obtained at diagnosis. Thirty-three
proteins, thereof 31 with an identified function, showed to be differentially abundant in the
proteomic analysis. Transcription factors and proteins involved in mRNA splicing dominated for the
patient group >200 colonies, whereas proteins involved in protein synthesis and modification (kinases)
were found to be decreased (Table 5; Supplementary Table S12). Two of the proteins had been studied in
AML previously: VIM (vimentin) and SMG1 (nonsense-mediated mRNA decay associated PI3K related
kinase). Vimentin (increased for the group >200 colonies) is considered a negative prognostic factor in
AML [26], whereas SMG1 (decreased for the group >200 colonies) is a potential tumor suppressor in
hypoxic tumors and associated with regulation of AML cell proliferation [27].
Phosphoproteomic analysis revealed 49 differentially phosphorylated proteins between the
two groups, including three proteins that were already identified by the proteomic analysis:
carboxypeptidase D (CPD), MAP7 domain containing 1 (MAP7D1) and VIM (Table 5; Supplementary
Table S13). Again, proteins involved in transcription, translation, and protein-modifying (19 proteins)
dominated, in addition to proteins involved in cytoskeleton structure and signaling (7 proteins).
As many as 12 proteins had been studied in AML previously. Expression of three of the proteins
is linked with mixed-lineage leukemia (MLL/11q23) rearranged AML: The transcription factors
DOT1L and ZNF521, and VIM. Furthermore, expression of four proteins is associated with tumor
progression/high risk AML: DOT1L, mTOR, VIM and ZNF521 [26–30], whereas the expression of six
proteins is associated with tumor suppression/low risk AML: AEBP2, CAST, CBFB, LSP1, MAP1S and
probably PCBP1 [31–35]. Finally, the effect of de/phosphorylation has been studied for LEO homolog
1 (LEO1), and dephosphorylation of this protein was then linked to leukemogenesis [36].
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Table 5. Classification of the proteins that were found to be differentially abundant (left) or differentially phosphorylated (right) for patient populations with >0.01%
clonogenic cells. The proteins with higher abundance are associated with transcription and lipid/ion transport. The differentially phosphorylated proteins, on the
other hand, are mainly linked with protein biosynthesis and the cytoskeleton. For details on the proteins, see Supplementary Tables S12 and S13.
Biological Process Proteomic Analysis Phosphoproteomic Analysis
Increased ≥200 Colonies Decreased ≥200 Colonies Increased ≥200 Colonies Decreased ≥200 Colonies
mRNA splicing RBMXL1; TXNL4A; ZNF830 PCBP1 2 PAPOLA; PRPF31; PRPF40A
Transcription MED1; POLR3C; ZNF830 SMG1 2 DOT1L 2; TCEAL3; ZNF521 2 CBFB 2; ISL2; LEO1 2; MYSM1
Transcription repressor SPEN; ZNF521 2 AEBP2 2; GATAD2B
Translation ABCF1; EIF2B2; FARSB; MRPL3 DNAJC2; EIF5B
Kinase CAMK2D; DGKZ; SMG1 2 NEK1; PRKD2
Chaperone DNAJC2; DNAJC5
Metabolism CPD 1; HEXB; MPDU1 USP4 CAST 2; CPD 1; DOT1L 2 CTPS1; MYO9B; PPP6R3; RASGRP2
Transporter, ion channel CLIC4; CPD 1; CRIP1; RALGAPA2 ABCF1; CLCN3; RBP4 CPD ATP13A1; OSBP; SCAP
Signaling RALGAPA2; VIM 1,2 CAP1; MRC2 VIM 1,2; ZFYVE26 LAT 2; LSP12; mTOR 2; RNF31; TMPO
Cytoskeleton VIM 1,2 AAMP; CAP1; MYOF SP100; VIM 1,2; ZFYVE26 DBNL; MYO9B; SH3BP1; TMPO
Apoptosis MED1; RMDN3; TMEM173 GRAMD4; MAP1S 2
Cell cycle/mitosis KIF4A NEK1
Proliferation regulation FAM53C; SCRIB
Others C19orf19/TRIR; MOB4 BOD1L1; CAD; IRF2BP2; TTC7A
Unknown GPALPP1 MAP7D1 1 MAP7D1 1; TOR4A
1 These proteins are found in both proteomic and phosphoproteomic analysis. 2 These proteins have been studied in AML.
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3. Discussion
In AML, the leukemic cells are organized in a hierarchy [10] and can be divided into three
different subgroups with decreasing percentage of the total amount of cells: (i) The non-cycling
blasts, which usually undergo apoptosis in cell culture during the first week; (ii) a subset of cells
with pro-longed self-renewal capacity (clonogenic cells); and (iii) a small subset of cells with a
long-term proliferative capability (4–8 weeks) in cell culture [7–9]. The latter include those cells
that are referred to as the leukemic stem cells (LSCs) that are usually associated with the CD34+CD38−
cell subpopulation [37]. Even though maturation is usually associated with loss of CD34 expression
and absence of long-term proliferation [8,9], exceptional patients present with CD34− LSCs [9,38,39].
Altogether, these observations fit with our present as well as previous studies [13] where colony
formation ability could neither be linked with FAB classification nor CD34 expression. Because the
fraction of cells with clonogenic potential is low (median: 1.6 × 10−2; mean: 0.16%) these cells can
virtually be present in any AML subtype. Since clonogenic blasts in certain cases even exist within the
more mature CD34− cell fraction, the cell marker CD34 itself can be used as a predictor neither for
colony formation [39] nor for patient survival [37].
One might debate, whether the observed colonies indeed are derived from long-term proliferating
leukemic cells or whether they result from contamination with normal hematopoietic stem cells (HSCs).
The latter view might be supported by the presence of erythroid colonies for some patients. However,
we regard the CFUs to be of leukemic origin. First, a previous study suggested that contamination
with healthy HSCs is common [40], and these cells may then proliferate in response to EPO and IL-3,
which are present in the MethoCult medium [41–43]. Therefore, one would expect to detect erythroid
CFUs for most cultures, but only 26% of patients presented with erythroid colonies after 7 weeks and
these colonies dominated only for five patients. Second, microarray analysis identified 36 differentially
expressed genes (Supplementary Figure S6; Supplementary Tables S10 and S11) between primary cell
populations with versus without erythroid colonies. The different expression patterns between these
two patient subgroups suggest that the observed difference lies within the leukemic cell populations,
which give rise to different colony types.
We saw an inverse correlation between an increased percentage of clonogenic cells (>0.01%) and
patient survival (Figure 1), which appears to be reasonable as these cells are expected to maintain the
disease. A larger fraction of blasts with long-term proliferative capacity thus might lead to increased
leukemic blast burden in the patients. Long-term replenishing of non-cycling cells could also be
observed in the cultures that contained the highest fractions of clonogenic cells, and these cultures
frequently (12/22 cultures with >200 colonies as opposed to 2/46 remaining cultures; Fisher’s exact
test, p < 0.0001) showed a higher number of viable cells after five weeks in suspension culture than the
originally seeded 2.0 × 106.
Previous studies have shown that AML patients differ in their requirements for proliferation
during in vitro culture [44–46]. Our present assay for long-term in vitro proliferation has two steps
that are based on different culture media; first five weeks of suspension culture followed by two
weeks of a methylcellulose-based clonogenic assay. The culture medium is thus different but highly
standardized in the two assays. Classification of patients as capable of long-term proliferation thus
requires survival of sufficient long-term proliferating cells during the first suspension culture, and the
ability to proliferate also in the second assay (weeks six and seven of in vitro culture). The two steps in
the long-term proliferation assay can explain why certain patients show discrepancies between the
numbers of viable cells after five weeks of suspension culture and the number of colonies in the final
clonogenic assay, where cultures presenting with few colonies showed a similar amount of viable cells
as cultures without colony formation.
We used primary AML cells derived from peripheral blood of AML patients with high percentages
and/or levels of circulating leukemia cells, and as discussed in detail in previous methodological
articles we thus have a selection of patients [7,47]. However, our patients should be regarded as
representative with respect to the most important biomarkers for in vivo chemosensitivity in AML,
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i.e., the generally accepted prognostic factors of this disease [47]. In addition, our study shows similar
frequencies of various mutants as previous studies of a general AML cell population have indicated [48].
Despite this, we want to emphasize that our results should be interpreted with care because we cannot
exclude the possibility that the cell populations are representative only for this selected subset of
patients. The advantage of our methodological strategy is that we used a simple and standardized
method for preparation of highly enriched AML cells without induction of functional alteration
due to more complex separation methods, e.g., antibody-based separation with ligation of surface
molecules [7,49]. Finally, the culture of similar AML cell population without subset selection has also
been used in previous studies of leukemic stem cells, i.e., long-term proliferating AML cells in the
presence of leukemia-supporting stromal cells (see [7,49]).
Another question is whether cells derived from the peripheral blood are representative for
the leukemic cells in the bone marrow microenvironment, which is regarded as the site of initial
leukemogenesis. A previous study compared the cell surface molecular profile for paired cell samples
derived from bone marrow and peripheral blood of the same patients; in these studies, the cells
showed only relatively small quantitative differences for a limited number of adhesion molecules [50].
Furthermore, in a recent study, we also showed that constitutive activation of the PI3K-Akt-mTOR
pathway varies considerably among patients but has large similarities when comparing paired blood
and bone marrow samples from the same patients [51]. These observations are not surprising when
taking into account that blood and bone marrow cells are hierarchically organized and are expected
to have the same AML-associated genetic abnormalities. Taken together, these observations suggest
that peripheral blood samples are representative for the AML cell population in general, but again we
would emphasize that our results should be interpreted carefully due to our analysis of peripheral
blood rather than bone marrow cells.
The constitutive cytokine secretion during long-term culture follows the same pattern for
a majority (13/19) of mediators, regardless of AML subclassification or long-term proliferation
capacity. Thus, the patient heterogeneity with respect to cytokine levels was to a large degree
maintained during culture. The cultures that differed from this pattern showed low proliferation
and low viability even during the first 2–8 days, indicating that apoptotic/necrotic cells do not
considerably contribute to mediator levels due to leakage through damaged/ruptured cell membranes.
An exceptional mediator is MMP-9. Even though the levels at week 5 are still highest for both blasts
with monocytic differentiation and with altered morphology, the start median values are divided in
half for these groups, whereas the concentrations increase by a 4-fold for FAB M0-2 and cells with
a stable phenotype. In addition, cultures with clonogenic cells show a trend towards an increase in
MMP-9 concentration over time. Together with HGF and IL-1RA–which significantly increased during
long-term culture–these were also the only cytokines where the absolute concentrations after five
weeks exceeded those of the cultures that lacked clonogenic cells (Supplementary Table S3).
Increased levels for HGF and IL-1RA for cell cultures containing clonogenic cells have been
reported previously [13]. At the detected concentrations (<100 ng/mL), IL-1RA stimulates AML
cell proliferation [52]. HGF has been thoroughly studied in AML, and enhanced release has been
associated with an adverse prognosis [53]. Inhibition of HGF expression in AML cell lines resulted
in increased apoptosis and reduced proliferation [54]. Furthermore, inhibition of the HGF-receptor
c-MET resulted in reduced colony formation ability of AML cells [55]. Targeting PI3K and mTOR
decreased supernatant levels of both HGF and MMP-9 [56]. MMPs play an important role in tumor
invasion and metastasis as they degrade extracellular matrix components [57,58]. Especially MMP-9
is associated with extramedullary infiltration and leukemia invasiveness [57,59]. It seems as if HGF
promotes cell cycle progression and blast proliferation, whilst inhibiting apoptosis, and increases the
expression of MMP-9 [54]. The increased levels of MMP-9 during pro-longed culturing of cultures
containing clonogenic cells might, therefore, be a consequence of the increased HGF levels. However,
it appears as if the MMP-9 increase during long-term culture is not a specific feature for cultures
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containing clonogenic cells. Rather than that, depletion of MMP-9 is correlated with cells that show
morphological alterations and may be involved in the change of phenotype.
In our present study, we observed a significant difference in supernatant levels only for a few of
the constitutively secreted cytokines when comparing cells with and without the capacity of long-term
proliferation. These levels reflect the balance between constitutive release, cytokine receptor binding
due to autocrine loops, and possibly degradation due to the release of proteases. However, the role
of soluble mediators in leukemogenesis is probably very complex, and we, therefore, emphasize that
only experiments based on cytokine knockdown, cytokine neutralization, or specific inhibition of
cytokine receptors and their downstream signaling can verify whether a certain cytokine is important
for the observed difference in long-term AML cell proliferation. Both receptor-blocking of HGF [55]
and the use of IL-1β specific antibodies [60] can reduce colony formation, verifying their involvement
in the process. Furthermore, as shown in neutralization experiments, even soluble mediators below
detection limit may contribute to cell proliferation [47], although the effects induced by the same
mediator may vary vastly among different patients [61–64]. Finally, autocrine effects of a cytokine
can be mediated both on intracellular/endogenous as well as extracellular loops [65]. Taken together,
differences in cytokine levels among patients (see Figures 2 and 3) do not necessarily reflect the
molecular mechanisms behind differences in long-term in vitro proliferation, whereas even mediators
with similar supernatant levels in the two patient groups may contribute to long-term proliferation
through differences in responsiveness towards the mediator. However, the observed cytokine
differences among patients with and without long-term proliferation (Figures 2 and 3) suggest that
these two subsets show additional differences with regard to communication via the local cytokine
network (i.e., IL-1/IL-1RA, HGF) with neighboring AML-supporting stromal cells in their common
bone marrow microenvironment.
We further observed that the cells which during the course of five weeks showed morphological
alterations had the highest constitutive cytokine levels after short-term (1 week) culture for 14/19
mediators (p ≤ 0.01), including IL-1RA, HGF and MMP-9 (Figure 4). The week 1 values were chosen
because these early measurements correspond the most to the originally cell cultures as (1) no cells have
been removed from the cultures, and (2) morphological alterations are not detectable yet. We also want
to stress that the 7-day cytokine profile is very similar to that obtained after only two days of culture:
55/68 of the samples were additionally cultured in StemSpan SFEMTM medium at a concentration
of 1.0 × 106 cells/mL for two days. The distribution of the patients into two groups with high and
low secretion of the same 14 cytokines showed a large degree of overlap with the cluster presented in
Figure 4 (Fisher’s exact test; p < 0.001). Cultures containing cells with an altered phenotype, therefore,
seem to present with an altered cytokine profile; this may explain why these cultures show significantly
increased cytokine levels for 7 mediators at week 5, even though the number of viable cells is lower than
in cultures with many clonogenic cells (median: 0.88 × 106 vs. 2.46 × 106 cells, respectively; p = 0.001).
Thus, the week 1 cytokine profile might predict a differentiation potential of the blasts and thereby a
favorable prognosis; this would be in agreement with our previous study where prolonged patient
survival was associated with a high constitutive cytokine secretion profile after 2 days in culture [14].
This improved survival might then be due to the leukemic cells’ capability to differentiate upon autocrine
cytokine stimulation. However, we have to stress that a high number of long-term proliferating cells
and an altered phenotype are not mutually exclusive as 50% of cultures with >200 colonies also showed
changes in morphology. Still, morphological changes during suspension culture were associated with
increased patient survival in our study (Supplementary Figure S4).
There are three reasons for why we chose to follow the change in phenotype by light
microscopy/cell morphology. First, tracking changes in morphology by light-microscopy has been
characterized in previous studies and should, therefore, be regarded as a reliable way to survey
alterations in the phenotype, i.e., a monocyte-macrophage differentiation program [66]. Second,
repeated evaluations during culture are allowed. Third, the alternative strategy of studying the
expression of a single or a few surface markers may reflect aberrant molecular expression (a well-known
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phenomenon in acute leukemia) rather than an altered phenotype [67]. Thus, in our opinion, this simple
methodological strategy is reliable, even though it does not allow any detailed examination.
We also compared the global gene expression profiles of primary AML cell populations with and
without more than 0.01% long-term proliferating cells. Since the fraction of clonogenic cells in the cell
population is small, it may not be surprising that few genes were found to be differentially expressed
between the two groups. Most of the downregulated genes for cultures >200 colonies are involved in
(energy) metabolism, whereas the upregulated genes especially code for proteins, which are involved
in cell cycle/mitosis and invasion. Of the latter, increased expression of GRB10 was associated with
Flt3-ITD, relapse, increased proliferation, reduced apoptosis and even increased colony formation
in short-term cultures (2 + 5 days) [17]. Since long-term culturing of AML blasts is not practical in
the clinic, these differentially expressed genes (Figure 5; Table 4) and especially GRB10 might act as
biomarkers in order to identify patients with a high fraction of long-term proliferating cells and, thus,
worsened prognosis.
We further found that mutations in the cohesin complex (represented by three of the five
proteins) and in ASXL1 are more frequent in the patient group with many clonogenic cells
(Supplementary Table S7). ASXL1, together with the cohesin complex, regulates gene expression
in normal hematopoietic cells. Mutations in ASXL1 lead to loss of function and altered expression
of cohesin target genes [68], and is therefore correlated with poor prognosis in AML [69]. On the
other hand, mutations in cohesin are also associated with loss of function, secondary AML, and poor
prognosis [70]. Interestingly, co-mutations in ASXL1 and cohesin genes also appear to be more frequent
in the patient group with more than 0.01% long-term proliferating cells. Thus, the loss of function of
several proteins with overlapping function might contribute to increased colony formation ability.
Finally, the proteomic analysis showed that many of the differentially abundant proteins are
involved in protein biosynthesis, from mRNA splicing to folding and modification of the nascent
protein (Table 5; Supplementary Table S12). Among these proteins were the negative prognostic factor
VIM and the tumor suppressor SMG1, which were found to be increased for the patients with many and
few colony forming cells, respectively. Regarding phosphoproteomics, we identified 49 differentially
phosphorylated proteins, of which 11 have been linked to prognosis in AML. Knockdown of two of
the proteins (histone methylating DOT1L and transcription factor ZNF521) has even shown to reduce
colony formation ability in short-term cultures [28,71]. It is remarkable that 40% of the differentially
phosphorylated proteins are involved in protein biosynthesis. We hypothesize that there might be a
link between the frequent gene mutations in AML and the aberrant phosphorylation profile in the
proteins with a similar function. Only six of the 35 patients with mutation data do not present with
mutations in epigenetic modifiers, transcription factors/repressors, spliceosome and cohesin complex
(Supplementary Table S7). Co-mutations in these gene groups are more frequent in the group with
many colonies (2.6 as compared to 1.5 mutations/patient; Fisher’s exact test p = 0.035). Therefore,
aberrant protein expression in AML cells with clonogenic ability might be reflected at both the gene
and the protein level.
Our hypothesis was that the ability of long-term in vitro growth in the absence of AML-supporting
non-leukemic cells differed among patients and had clinical relevance. The obtained results strongly
suggest that this is true. However, we also hypothesized that differences in the capacity of long-term
in vitro proliferation are due to differences in the regulation of AML cell proliferation and/or the
balance between pro- and anti-apoptotic signaling; while this may be true, the molecular mechanisms
behind these differences still remain to be resolved.
4. Materials and Methods
4.1. Patients and Preparation of AML Cells
The study was approved by the local Ethics Committee (Regional Ethics Committee III, University
of Bergen, REK 2017-305, Bergen, Norway) and samples were collected after written informed consent.
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AML blasts from peripheral blood were derived from 68 unselected patients with a high number
and/or percentage of circulating leukemic cells (33 females and 35 males; median age 64 years with
range 18–92 years). A majority of 45 patients had de novo AML whereas 7 patients had relapsed
AML, and 19 patients had AML secondary to chronic myeloproliferative neoplasia, myelodysplastic
syndromes or previous chemotherapy (Table 1). Thirty-five of the patients received potentially curative
treatment including induction therapy based on cytarabine plus an anthracycline followed by intensive
consolidation treatment.
4.2. Preparation of Enriched AML Cells
AML cells were isolated from peripheral blood by density gradient separation (Lymphoprep;
Axis-Shield, Oslo, Norway; specific density 1.077 g/mL) and due to our selection of patients with high
absolute/relative levels of circulating AML cells the gradient-separated cell populations contained
at least 90% leukemia cells. The cells were cryopreserved and stored in liquid nitrogen [62]. All cell
samples were isolated, cryopreserved, and thawed based on the same highly standardized methods.
4.3. Analyses of AML Cell Viability and Short-Term Proliferation
4.3.1. Analysis of AML Cell Viability
AML cells were cultured for 40 h in Stem Span SFEMTM medium (Stem Cell Technologies;
Vancouver, BC, Canada) and cell viability analyzed by flow cytometry using propidium iodide-Annexin
V (Tau Technologies BV; Kattendijke, The Netherlands) staining as described previously [14].
4.3.2. Proliferation Assay
As described in detail previously [14], AML cells were cultured for one week in serum-free
Stem Span in the presence of Flt3L, SCF and GM-CSF, until proliferation was assayed as nuclear
3H-thymidine incorporation after 8 days. Detectable proliferation was defined as nuclear incorporation
corresponding to >1000 cpm.
4.4. Long-Term Suspension Cultures
AML cells were cultured in Endothelial Cell Growth Medium (EGM-2 medium, Lonza;
Walkersville, MD, USA), which contains, among others, 2% fetal bovine serum and vascular endothelial
growth factor (VEGF) to facilitate rapid proliferation. According to the manufacturer’s descriptions,
the medium was further supplemented with 20 ng/mL of TPO, Flt3L, SCF, GM-CSF and IL-3
(Peprotech; Rocky Hill, NJ, USA). The EGM-2 medium has shown to support the long-term proliferation
of AML blasts [13].
We initially seeded 2 × 106 AML cells in 5 mL EGM-2 medium in 6-well tissue plates (Nunc;
Roskilde, Denmark), and the cells were incubated in suspension cultures for five weeks. Once a week,
1–2 mL of medium or cell suspension—for cultures containing high cell density as judged by light
microscopy—was removed and replaced by fresh complete EGM-2 medium. Cell supernatants were
harvested after week 1 and week 5 and stored at −80 ◦C prior to analysis.
4.5. Colony Formation Assay
Long-term cultured cells were tested in our colony formation assay after five weeks of suspension
culture. The non-adherent AML cells were then collected, centrifuged, and resuspended in 0.5 mL
RPMI medium (Sigma Aldrich; St. Louis, MO, USA). The number of viable cells was determined
using trypan blue staining (Fluka; St. Louis, MO, USA). Subsequently, duplicates of 2.5 × 104 and,
where available, 5.0 × 104 viable AML cells were seeded in 0.5 mL MethoCultTM H4434 classic
medium (StemCell Technologies; Vancouver, BC, Canada) containing EPO in flat-bottomed 24-well
plates (Nunc). Lower viable cell numbers were seeded for patients with low cell populations after five
weeks in culture. After an additional 14 days of in vitro culture in the colony formation assay colonies
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containing more than 30 cells (i.e., CFUs) were scored using an inverted microscope. Colonies were
classified as being of either myeloid or erythroid origin, where the latter showed morphological signs
of hemoglobinization.
4.6. Analysis of Soluble Mediator Levels in Cell Culture Supernatants
The sampled cell culture supernatants were analyzed by Luminex (R&D Systems;
Minnesota, MN, USA). Excretion levels for following 19 proteins were measured: (i) The chemokines
CCL2-5, CXCL1/5/8/10; (ii) the interleukins IL-1β, IL-1RA and IL-6; (iii) the growth factors G-CSF and
HGF; (iv) the matrix metalloproteases MMP-1/2/9; (v) the protease inhibitors cystatin C and serpin E1;
and (vi) TNFα.
4.7. RNA Preparation and Analysis of Global Gene Expression
RNA preparation, labeling, and microarray hybridization have been described in detail
previously [72]. Briefly, the gene expression profiles were analyzed using the Illumia iScan Reader
(Illumina Inc., San Diego, CA, USA) for fluorescent detection of biotin-labeled complementary RNA
(cRNA). The latter was quality-controlled by both NanoDrop and an Agilent 2100 Bioanalyzer
(Agilent Tachnologies, Santa Clara, CA, USA). Finally, 750 ng biotin-labeled cRNA was hybridized to
the HumanHT-12 V4 Expression BeadChip (Illumina Inc.), which targets 47,231 probes. The microarray
data were quantile normalized prior to analysis in J-Express 2012 (MolMine AS, Bergen, Norway) [73].
4.8. Proteomic and Phosphoproteomic Analyses
The methods for analysis of proteomic and phosphoproteomic profiles in primary human AML
cells have been described in detail previously [74–76]. Briefly, each patient sample was spiked
with a heavy super-SILAC mix [77] and prepared according to the filter-aided sample preparation
protocol [78] for proteome and phosphoproteome analysis using nano-liquid chromatography online
coupled with a QExactive HF Orbitrap mass spectrometer (Thermo Scientific, Bremen, Germany).
4.9. Statistical and Bioinformatical Analyses
The statistical analyses were performed with the IBM Statistical Package for the Social Sciences
(SPSS) version 25 (Chicago, IL, USA) and with GraphPad Prism 5 (San Diego, CA, USA). The Wilcoxon
signed-ranked test was used to compare paired samples, whereas Mann-Whitney U-tests and
Kruskal-Wallis tests were used to compare different patient subgroups. The χ2 test was used to
analyze categorized data and the Kendall’s tau-b test for correlation analyses. Finally, Kaplan Meier
analysis and log-rank test in addition to Cox regression for multivariate analyses were used for patient
survival statistics. In general, p-values < 0.05 were regarded as statistically significant.
The statistical analyses of proteomic and phosphoproteomic data were performed with a Welch
t-test in Perseus (Max Planck Institute of Biochemistry, Martinsried, Germany) [79], and the significance
of fold changes was assessed using Z-statistics [80].
For hierarchical clustering of the cytokine release levels, all values were median normalized and
log transformed prior to clustering using J-Express (MolMine AS, Bergen, Norway). Complete linkage
and cosine correlation were used as the linkage method and distance measurement, respectively.
5. Conclusions
In this study, more than half of the AML patients had cells with long-term (i.e., seven weeks)
proliferative capacity and/or a stable phenotype during culture; both these characteristics are associated
with an adverse prognosis for patients receiving intensive induction therapy. Strikingly, these two
parameters were not associated with other unfavorable prognostic factors. Cultures containing
clonogenic cells presented with a higher increase in HGF and IL-1RA concentrations than the others
during culture, and had, in general, higher numbers of viable cells after 5 weeks in suspension culture.
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From our results, it appears as if aberrant transcription and transcription regulation is associated with a
high percentage of clonogenic cells, as genes involved in transcription more frequently are mutated for
these patients, and proteins which are involved in protein synthesis are overexpressed or differentially
phosphorylated for the patient group. Thus, these characteristics may be used to predict the presence of
many clonogenic cells at the time of diagnosis, and thus an adverse prognosis.
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